Skip to main content

Nihon Medi-Physics Co., Ltd.

Contributing to medical care as a leading radiopharmaceutical firm.

  • Site Map
  • Japanese
Enter the terms you wish to search for.
  • Company Profile
    • Top Message
    • Vision and Management Policy
    • Overview
    • History
    • Locations of Offices and Facilities
  • Our Business
    • Business fields
    • For optimal use of our product
    • Product supply system
    • Research and Development
    • Non-clinical PET molecular imaging business
  • Our Products
  • For Recognition of Nuclear Medicine
    • Conferences / Exhibitions
    • Collaboration with academic societies
    • Technical workshop by Imaging Information Technology Center
    • Wagner-Torizuka Fellowship
Our mission is to deliver consistently high quality products and to develop new values in medical care technology.  With our nationwide operation network, we keep challenging toward further benefit of patients in harmony with healthcare professionals.(slide1)
Our mission is to deliver consistently high quality products and to develop new values in medical care technology.  With our nationwide operation network, we keep challenging toward further benefit of patients in harmony with healthcare professionals.(slide2)
Our mission is to deliver consistently high quality products and to develop new values in medical care technology.  With our nationwide operation network, we keep challenging toward further benefit of patients in harmony with healthcare professionals.(slide3)
Our mission is to deliver consistently high quality products and to develop new values in medical care technology.  With our nationwide operation network, we keep challenging toward further benefit of patients in harmony with healthcare professionals.(slide4)
  • 0
  • 1
  • 2
  • 3

Company Profile

Our Business

Our Products

For Recognition of Nuclear Medicine

Press Release

April 5, 2022
Nihon Medi-Physics Attains World’s First Manufacturing of Actinium-225 with Cyclotron on Production Scale for Investigational Drugs - Core Material Used for Targeted Alpha Therapy (TAT) Expected to Be Novel Treatment for Cancer -
20220405_newsrelease_ac225_e.pdf716.66 KB
June 15, 2020
Nihon Medi-Physics and Global Medical Solutions Announce Strategic Partnership in Nuclear Medicine Markets in Asia and Oceania
ENG_20200615_Press Release_GMS.pdf841.44 KB
October 11, 2019
Nihon Medi-Physics Accelerates “Theranostics” Development
Press Release_191011_Theranostics.pdf458.74 KB
October 11, 2019
Nihon Medi-Physics Launches In-house Production of Molybdenum-99
Press Release_191011Molybdenum-99.pdf262.55 KB
July 3, 2019
Nihon Medi-Physics and Combinostics Enter into an Exclusive Agreement to Develop and Market Software Diagnosing Dementia
20190703.pdf610.71 KB
See more

Nihon Medi-Physics Co., Ltd. logo

About the contents of this website

Product information in this Website is provided to offer general information on the Company’s pharmaceutical products. It is not intended to provide medical advice or usage descriptions of the Company’s pharmaceutical products. This Website is not to be used as an alternative for medical practitioners such as physicians and pharmacists to consult with patients in order to determine medical treatments. In addition, the information about the products (including products under development) on this Website does not constitute a promotion or commercial advertisement of the product or its efficacy.

Product information provided on this Website is intended for medical practitioners for use in Japan, and the contents therein are based on approvals that have been granted in Japan. If you are accessing this Website from outside of Japan, please be aware that the product information available on this Website might not be appropriate for you. Please confirm the approval status and content in your relevant country.

Do you agree?
YES
NO
  • About Our Site

Copyright © Nihon Medi-Physics Co.,Ltd. All Rights Reserved.

このページの先頭へ